Caffeine Neuroprotection Decreases A2A Adenosine Receptor Content in Aged Mice. 2019

Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
Laboratório de Biologia Celular e Molecular, Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense - UNESC, Criciúma, SC, Brazil.

Caffeine is a bioactive compound worldwide consumed with effect into the brain. Part of its action in reducing incidence or delaying Alzheimer's and Parkinson's diseases symptoms in human is credited to the adenosine receptors properties. However, the impact of caffeine consumption during aging on survival of brain cells remains debatable. This work, we investigated the effect of low-dose of caffeine on the ectonucleotidase activities, adenosine receptors content, and paying particular attention to its pro-survival effect during aging. Male young adult and aged Swiss mice drank water or caffeine (0.3 g/L) ad libitum for 4 weeks. The results showed that long-term caffeine treatment did not unchanged ATP, ADP or AMP hydrolysis in hippocampus when compared to the mice drank water. Nevertheless, the ATP/ADP hydrolysis ratio was higher in young adult (3:1) compared to the aged (1:1) animals regardless of treatment. The content of A1 receptors did not change in any groups of mice, but the content of A2A receptors was reduced in hippocampus of mice that consumed caffeine. Moreover, the cell viability results indicated that aged mice not only had increased pyknotic neurons in the hippocampus but also had reduced damage after caffeine treatment. Overall, these findings indicate a potential neuroprotective effect of caffeine during aging through the adenosinergic system.

UI MeSH Term Description Entries
D008297 Male Males
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000066829 Neuroprotection The physiological processes and techniques used by the body to prevent neuronal injury and degeneration in the central nervous system following acute disorders or as a result of chronic neurodegenerative diseases. Neural Protection,Neuron Protection,Neuronal Protection,Protection, Neural,Protection, Neuron,Protection, Neuronal
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D043705 Receptor, Adenosine A2A A subclass of adenosine A2 receptors found in LEUKOCYTES, the SPLEEN, the THYMUS and a variety of other tissues. It is generally considered to be a receptor for ADENOSINE that couples to the GS, STIMULATORY G-PROTEIN. Adenosine A2A Receptor,Adenosine A(2A) Receptor,Adenosine A2A Receptors,A2A Receptor, Adenosine,A2A Receptors, Adenosine,Receptors, Adenosine A2A
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D058917 Adenosine A2 Receptor Antagonists Compounds that selectively bind to and block the activation of ADENOSINE A2 RECEPTORS. Adenosine A2A Receptor Antagonists,Adenosine A2B Receptor Antagonists

Related Publications

Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
April 2003, British journal of pharmacology,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
October 1997, Annals of the New York Academy of Sciences,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
January 2004, Critical reviews in neurobiology,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
July 2022, British journal of pharmacology,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
December 2003, Neurology,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
February 2006, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
January 2002, Journal of neurochemistry,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
December 2003, Neuropharmacology,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
January 2021, Frontiers in molecular biosciences,
Michelle Lima Garcez, and Adriani Paganini Damiani, and Robson Pacheco, and Lucas Rodrigues, and Larissa Letieli de Abreu, and Márcio Correa Alves, and Vanessa Moraes de Andrade, and Carina Rodrigues Boeck
January 2008, Frontiers in bioscience : a journal and virtual library,
Copied contents to your clipboard!